A trial-based cost-effectiveness analysis of erlotinib alone versus platinum-based doublet chemotherapy as first-line therapy for Eastern Asian nonsquamous non-small-cell lung cancer
about
Chemotherapy regimens for metastatic nonsmall cell lung cancer: Generating good quality data is important before challenging evidence.Cost-effectiveness of lung cancer screening and treatment methods: a systematic review of systematic reviews.Economic Impact of Tissue Testing and Treatments of Metastatic NSCLC in the Era of Personalized MedicineA systematic review of the cost-effectiveness of targeted therapies for metastatic non-small cell lung cancer (NSCLC)Economic evaluation of first-line and maintenance treatments for advanced non-small cell lung cancer: a systematic reviewCost-effectiveness analyses of targeted oral anti-cancer drugs: a systematic review.Cost-effectiveness of first-line erlotinib in patients with advanced non-small-cell lung cancer unsuitable for chemotherapyTrial-Based Cost-Utility Analysis of Icotinib versus Gefitinib as Second-Line Therapy for Advanced Non-Small Cell Lung Cancer in ChinaEconomic Evaluation of Companion Diagnostic Testing for EGFR Mutations and First-Line Targeted Therapy in Advanced Non-Small Cell Lung Cancer Patients in South KoreaIntratumoral chemotherapy for lung cancer: re-challenge current targeted therapies.The safety and efficacy of osimertinib for the treatment of EGFR T790M mutation positive non-small-cell lung cancer.Quality of pharmacoeconomic research in China: A systematic reviewCost-effectiveness analysis of EGFR mutation testing in patients with non-small cell lung cancer (NSCLC) with gefitinib or carboplatin-paclitaxel.Transcutaneous electrical acupoint stimulation (TEAS) relieved cancer-related fatigue in non-small cell lung cancer (NSCLC) patients after chemotherapy.The role of health economics and outcomes research in health care reform in ChinaRedox-responsive and pH-sensitive nanoparticles enhanced stability and anticancer ability of erlotinib to treat lung cancer in vivo.Economic Considerations in the Use of Novel Targeted Therapies for Lung Cancer: Review of Current Literature.OPTIMAL and ENSURE trials-based combined cost-effectiveness analysis of erlotinib versus chemotherapy for the first-line treatment of Asian patients with non-squamous non-small-cell lung cancer.Diamond: immunohistochemistry versus sequencing in EGFR analysis of lung adenocarcinomas.Flipped script for gefitinib: A reapproved tyrosine kinase inhibitor for first-line treatment of epidermal growth factor receptor mutation positive metastatic nonsmall cell lung cancer.
P2860
Q31125762-E57AED22-C35C-48E5-A01F-72C70D3828C7Q33814897-C5BDDEA1-2493-48ED-A7A5-7535E8889E15Q34219452-DBF581FC-09E0-4778-806C-B540994AA9F8Q34727967-203E2061-9B07-4AC6-8F6B-6667FC695F3CQ34742887-02DB0348-BB68-4779-8B47-3D06262E0D57Q35167535-D3729E55-7746-47AE-88BA-ED6ED634F40DQ35844278-2E59C3C6-64CC-4E02-ADDE-E8F53ED0BA45Q35970324-766D0322-7D10-4CAE-90F4-8F4831427459Q36092393-EAE1927D-02F0-43ED-8D5C-E5750103EBDBQ37033793-8202DACF-4F63-4CA5-857E-9E6399A24F70Q37085219-8114CB38-628F-43D2-8E65-9C5BE1C166D3Q37354823-0F6D64DB-23D7-4C5C-93EE-9A0FF38D4017Q40575534-E0826289-F946-4F08-B084-3F73B3859AE4Q41241676-1E03E219-5F7E-4524-AD84-F0DB7502C149Q42428288-9818CB3D-5632-4096-B809-E69C6D5E95B0Q47135282-702BFF5C-E04D-4A1E-A3EC-FD04F53DB760Q50238133-56074712-D584-42F3-9D31-85405AB6011EQ52589245-96FB2090-5073-4AC5-8A02-64ECBAF91E07Q52903547-D719C504-15B4-430D-82CA-10A82495984EQ55030214-8887B99E-3AD8-49A5-B11F-5B42CF3829E5
P2860
A trial-based cost-effectiveness analysis of erlotinib alone versus platinum-based doublet chemotherapy as first-line therapy for Eastern Asian nonsquamous non-small-cell lung cancer
description
2013 nî lūn-bûn
@nan
2013 թուականին հրատարակուած գիտական յօդուած
@hyw
2013 թվականին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
A trial-based cost-effectivene ...... ous non-small-cell lung cancer
@ast
A trial-based cost-effectivene ...... ous non-small-cell lung cancer
@en
A trial-based cost-effectivene ...... ous non-small-cell lung cancer
@nl
type
label
A trial-based cost-effectivene ...... ous non-small-cell lung cancer
@ast
A trial-based cost-effectivene ...... ous non-small-cell lung cancer
@en
A trial-based cost-effectivene ...... ous non-small-cell lung cancer
@nl
prefLabel
A trial-based cost-effectivene ...... ous non-small-cell lung cancer
@ast
A trial-based cost-effectivene ...... ous non-small-cell lung cancer
@en
A trial-based cost-effectivene ...... ous non-small-cell lung cancer
@nl
P2093
P2860
P3181
P1433
P1476
A trial-based cost-effectivene ...... ous non-small-cell lung cancer
@en
P2093
Chongqing Tan
Lihui Ouyang
Liubao Peng
Siying Wang
Xiaohui Zeng
P2860
P304
P3181
P356
10.1371/JOURNAL.PONE.0055917
P407
P577
2013-01-01T00:00:00Z